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bstract Objective: To establish the functional significance of endogenous peptide YY (PYY) and neu-
ropeptide Y (NPY) as mediators of Y1 and Y2 absorptive tone in colonic mucosa.
Methods: Functional studies utilized descending colon from adult mice (wild type [WT] and
peptide nulls) and ex vivo human colonic tissue (from patients undergoing bowel resections)
measuring changes in basal ion transport. Peak increases in ion transport to Y1 or 2 antagonists
(BIBO3304 300 nM; BIIE0246 1 M) were pooled (mean  SEM) and compared using Student’s
unpaired t test (P  0.05); some tissues received tetrodotoxin (TTX; 100 nM). PYY-positive L-cell
numbers and NPY innervation were also compared.
Results: Y1 and Y2 tones were present in human and WT mouse colon mucosa and only the latter
was TTX sensitive. Y1 tone was unchanged in NPY/ but was 90% inhibited in PYY/ and
abolished in PYYNPY/ colon mucosa. Y2 tone was reduced 50% in NPY/ and PYY/
tissues and was absent from PYYNPY/ colon. Residual Y2 and Y1 tones present in PYY/
mucosa were abolished by TTX. PYY ablation had no apparent effect on NPY innervation and
PYY-positive cells were observed at the same frequency in NPY/ (56.7  6.8 cells/section) and
WT (55.0  4.6 cells/section) colons. Double knockouts lacked PYY and NPY expression, but
endocrine cells and enteric nerves were present with similar frequencies to those of WT mice.
Conclusion: Endogenous PYY mediates Y1 absorptive tone that is epithelial in origin, whereas Y2
tone is a combination of PYY and NPY mediation. 
© 2008 Elsevier Inc. 
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Peptide YY (PYY) and neuropeptide Y (NPY) are po
ntisecretory peptides. Healthy human subjects infused w
ither peptide exhibit prolonged inhibition of pre-stimula
lectrolyte secretion [1,2]. Recent functional studies uti
ng selective Y-receptor antagonists and preferred pept
gonists have shown that PYY, NPY, their C-terminal 
ents, and pancreatic polypeptide (PP) exert their sustai
ntisecretory actions via specific Y receptors, (Y1, 2, and
4) and that in human and mouse colons the same th
eceptors are involved [3– 6]. However, clinical stu
dentifying the Y-receptor types responsible for these an
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Open access under CC BY license.arrheal actions have not been reported to date. Studies 
x vivo human colon have shown the presence of signifi
evels of Y1- and Y2-mediated absorptive tones [4,5]. I
ddition, mouse colon (but not other rodent colons) exh
1 and Y2 tone [5–7] and the similarity in pharmacolo
xhibited by this rodent model and human tissue prov
n opportunity to investigate the cellular mechanisms
bsorptive tone further. This report is based on an in
ecture to the 9th International NPY meeting (Okina
arch 2008) and focuses on the local mucosal effec
ndogenous PYY and NPY.
eptides: their locations and functions in the intestine
Peptide YY is expressed predominantly in colorectal
ndocrine L-cells [8,9] and is colocalized with proglucagon
roducts, glicentin and glucagon-like peptide-1 (GLP-1)
nd GLP-2 [10]. These peptides are copackaged [10,11] and
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901H. M. Cox / Nutrition 24 (2008) 900–906o-released when food reaches the duodenum. PYY is also
ound in pancreatic endocrine F-cells, often with PP. In the
nteric nervous system, NPY is present in 50% of sub-
ucous plexus neurons, the majority of which innervate the
ucosa and target the lamina propria of most species, in-
luding rat, mouse, and human colon [12,13]. Within the
ubmucous plexus, NPY is most frequently present in se-
retomotor nerves and is colocalized with the inhibitory
eurotransmitter, vasoactive intestinal polypeptide [12,14].
P, in contrast, is present in a sparse population of
ndocrine cells scattered along the length of the intestine
n most species [9,10], its primary source being the pan-
reatic F-cells.
Dietary fat, bile salts, carbohydrates, and proteins can
timulate PYY release but to different degrees and with
ifferent rates (for review, see Onaga et al. [15]). PYY
elease is also regulated by, and in turn regulates, vagal
erve activity [15] and the hormone is a major mediator of
leal and colonic brakes, mechanisms that ultimately slow
astric emptying and promote digestive activities to in-
rease nutrient absorption [16–18]. In the circulation40%
f released PYY is converted to PYY(3–36) [19,20] and the
onsequence of this conversion is to amplify Y2-mediated
echanisms at the expense of Y1 (and Y4) responses, be-
ause the long fragments have a low affinity for the latter
eceptors. This hydrolysis occurs via the serine protease,
ipeptidyl peptidase-4 (DPP4; EC 3.4.14.5), which cleaves
minoterminal dipeptides from NPY with a higher maxi-
um activity than from PYY [20]. The switching of recep-
or activities is likely to be important in modulating diges-
ive behavior and in initiating satiety consequent to
ostprandial increases in plasma PYY and PYY(3–36).
PP4 inhibitors are clinically important because they also
rolong the half-life of incretin hormones, GLP-1 and
LP-2 [21], both of which lower blood glucose in a glucose-
ependent manner. The inhibitors’ potential as new treat-
ents for type 2 diabetes is proven [22] but a proportion of
heir effects (i.e., promoting satiety and reducing food in-
ake and subsequently body weight) are likely to be medi-
ted by increased half-lives of unrelated peptides, e.g., PYY
r NPY, whose prolonged stability (together with other
PP4 substrates [23]) may result in acute intestinal side
ffects.
receptors: their locations and implications for intestinal
unction
Exogenous PYY, NPY (their fragments), and PP are
otent, broad-spectrum inhibitors of electrolyte secretion in
uman [2,4] and mouse [3,5] intestines and functional stud-
es utilizing genetically modified mice lacking a Y receptor
Y1/, Y2/, or Y4/) combined with selective Y1 [24]
r Y2 [25] antagonists and neurotoxin-treatment have
hown that Y1 and Y4 are predominantly epithelial, whereas
2 receptors are neuronal (Y5 (ant)agonists have no effect)3–5]. Y1/ mouse tissues are predictably insensitive to Y1 Kgonists and selectively lack Y1 absorptive tone, whereas
2 tone and Y2 agonist sensitivity are unaltered [7]. Chem-
cal depolarization of intrinsic submucous neurons (with
eratridine) causes sustained epithelial responses that are
ot altered by Y1 antagonism (BIBO3304) or ablation (i.e.,
n Y1/ tissue [7]). Predictably Y2/ mucosa is Y2 ago-
ist–insensitive and lacking in Y2 absorptive tone but Y1
one is unchanged [5]. Neurogenic mucosal responses in
ild-type (WT) colon are amplified by Y2 antagonist pre-
reatment and are significantly increased in Y2/ colon [5].
rrespective of these differences in cellular localization,
-receptor activation leads consistently to prolonged anti-
ecretory effects.
Immunohistochemical studies have revealed extensive
1 labeling on epithelial basolateral membranes and dis-
rete labeling of intrinsic neurons in the lamina propria of
ediatric and adult human colon [13,26]. PYY-positive en-
ocrine cells are often surrounded by Y1-immunoreactive
pithelia and nerve fibers but are themselves Y1-negative
26]; thus a paracrine rather than an autocrine action for
YY is likely to be significant in human colon. In the rat
ntestine numerous Y1-positive cell bodies have been ob-
erved in myenteric but not in submucous ganglia [27],
mplicating a neuromodulatory role in smooth muscle ac-
ivity in this species. In rat jejunum and colon Y2 expression
ccurs in epithelial and muscle layers [28] but as yet no
mmunohistochemical Y2-receptor localization in the intes-
ine has been described. Notably, Y2 or Y1 absorptive tone
s absent in rat gastrointestinal tissues [29]. In human and
ouse colon mucosae, however, there is significant en-
ogenous Y2 tone, which appears to be neurogenic [3,5]
nd is therefore more likely to be NPY rather than PYY
ediated [7].
Despite growing pharmacological evidence, a better un-
erstanding of the endogenous mechanisms underpinning
onic absorption is a prerequisite if Y receptors are to be
onsidered potential targets for treating malabsorption.
herefore, we set out to establish whether endogenous PYY
as responsible for Y1 absorptive tone and NPY-mediated
2 tone, making use of single (PYY/ and NPY/) and
ouble (NPYPYY/) knockout mice in conjunction with
uman colonic tissue.
aterials and methods
BIBO3304 and BIIE0246 were gifts from Boehringer-
ngelheim Pharma KG (Biberach an der Riss, Germany) and
tocks in 10% dimethyl sulfoxide were stored at 20°C.
eptides were from Bachem Laboratories Inc. (St. Helens,
nited Kingdom). The DPP4 inhibitor, compound 3, was a
ift from Dr. R. Roy (Merck Inc., Rahway, NJ, USA).
nti-PYY (from Dr. E. Ekblad, University of Lund, Lund,
weden), anti–C-terminal peptide or NPY and anti-NPY
ntibodies (Affiniti Research Products Ltd., Exeter, United
ingdom), and goat anti-rabbit fluorescein isothiocyanate–
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902 H. M. Cox / Nutrition 24 (2008) 900–906r tetramethylrhodamine isothiocyanate–conjugated sec-
ndary antibodies (BIOMOL International, Exeter, United
ingdom) were used. All other compounds were of analyt-
cal grade (Sigma-Aldrich, Poole, United Kingdom).
easurement of ion transport and Y1 and Y2 absorptive
one in isolated mucosal preparations
Colon mucosa from clinical specimens obtained from
onsenting patients undergoing bowel resection surgery
three men and one woman; Table 1) or from WT and
nockout mice of different genotypes (NPY/, PYY/
30] and double knockouts, 16–24 wk old, either gender,
ith a mixed C57BL/6–129/SvJ background, fed standard
how) were prepared by removing overlying smooth muscle
nd voltage-clamped at 0 mV in Ussing chambers as de-
cribed previously [3,4]. Vectorial ion transport (Isc) was
easured continuously as microamps per square centimeter
nd all additions were basolateral. Once stable basal Isc
evels were achieved, mucosae were pretreated with vehicle,
he DPP4 inhibitor (1 M of compound 3, [22]) or tetro-
otoxin (TTX; 100 nM). Treatment periods were 20–30
in before the addition of the Y1-receptor antagonist
IBO3304 (300 nM [24]), the inactive enantiomer of
IBP3226, BIBP3435 (1 M, 3435), or the Y2 selective
ntagonist BIIE0246 (1 M [25]). The maximum rise in Isc
15–25 min) after each Y antagonist was pooled and com-
ared with controls.
mmunohistochemistry
Lengths (2–3 cm) of mouse descending colon were
ashed in KH buffer and immersed in paraformaldehyde
4%) for 24 h, washed well in phosphate buffered saline
PBS), cryoprotected in 30% sucrose in PBS for 48 h before
eing embedded in OCT (VWR International, Lutterworth,
K), and stored at 80°C. Sections (15 m) were cut,
ehydrated in PBS, and blocked in 10% normal goat serum
n PBS for 2 h before incubating overnight in polyclonal
nti-PYY antibody (1:1000) to visualize PYY-containing
able 1
ge and gender comparisons with basal resistance and Isc levels and the
urine colon*
Age No./gender
umans 71.3  7.0 y (4) 3/M, 1/F
ice
WT 18.5  1.2 wk (17) 15/M, 2/F
NPY/ 24.1  1.4 wk (9) 5/M,4/F
PYY/ 18.3  3.3 wk (7) 7/M
NPYPYY/ 16.3  0.5 wk (4) 4/F
F, female; Isc, short-circuit current; M, male; ND, not determined; NPY
ouble knockout; PYY/, peptide YY single knockout; TTX, tetrodotox
* Values are means  SEMs (numbers of observations).
† P  0.05 compared with WT controls.ndocrine cells or in chromogranin A (1:400) to label all andocrine cells. Longer incubation times (3–4 d) were used
o enable anti-NPY labeling (1:400) of NPY-containing
eurons or protein gene product (PGP)9.5 (1:400) labeling
f all enteric neurons. Primary antibodies were visualized
ith goat anti-rabbit F(ab=)2 secondary antibodies conju-
ated to fluorescein isothiocyanate or tetramethylrhodamine
sothiocyanate (used at 1:200 for 2 h at room temperature;
hemicon, Harrow, UK). The sections were washed in PBS,
ounted in Fluorosave (Calbiochem, Nottingham, UK), and
iewed with a Provis microscope fitted with appropriate
lters and Axiovision software, and the numbers of fluores-
ent endocrine cells were counted and innervation com-
ared between genotypes.
ata analyses
Maximal changes in Isc at 15 or 25 min are expressed
hroughout as mean  SEM from a minimum of three
xperiments. Single comparisons between data groups were
erformed using Student’s unpaired t test, whereas multiple
omparisons used one-way analysis of variance with Dun-
ett’s post-test with P  0.05 considered statistically sig-
ificantly different.
esults
Table 1 presents the basal resistances and Isc levels for
uman and murine colon mucosae. Values were similar to
hose published previously for human and WT mouse mu-
osae [5,6] and basal levels of Isc and TTX-sensitive Isc in
PY/ colon specifically were significantly higher than
hose of WT tissue. The competitive Y1 antagonist,
IBO3304, caused sustained elevations in Isc that were
aximal at 15 min in WT mouse and human colon mucosa
nd neither of these effects was sensitive to TTX pretreat-
ent (Fig. 1A,C). The inactive Y1 antagonist enantiomer,
IBP3435, had no effect per se (P  0.01 in both tissues).
lockade of Y2-mediated absorption (with Y2 antagonist
IIE0246) also increased basal Isc levels that were virtually
of neuronal blockade by TTX in mucosal preparations from human and
stance (, cm2) Basal Isc (A/cm2) TTX (A/cm2)
 4.9 (21) 72.0  7.6 (21) 30.5  5.3 (7)
 1.8 (52) 55.3  5.6 (52) 3.6  1.3 (17)
 2.7 (18) 82.6  8.6 (18)† 9.4  1.8 (7)†
 3.0 (20) 73.9  9.8 (20) 8.6  2.8 (6)
 3.1 (8) 51.9  15.1 (8) ND
uropeptide Y single knockout; NPYPYY/, peptide YY/neuropeptide Y
, wild-type.effect
Resi
75.5
29.3
28.2
37.3
24.8
/
, ne
in; WTbolished by the neurotoxin TTX (Fig. 1B,D). This indi-
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903H. M. Cox / Nutrition 24 (2008) 900–906ates that Y2 tone is predominantly neuronal in contrast to
1 absorptive tone that is non-neuronal in both colonic
issues.
Because NPY is a better substrate for DPP4, Y2 tone was
redicted to be amplified by a selective DPP4 inhibitor.
hereas Y1 tone was unaffected in mouse or human mu-
osa (data not shown), the same pretreatment with com-
ound 3 significantly augmented Y2 tone at 25 min in
uman mucosa (control [n  4] 9.6  4.7 A/cm2 versus
ompound 3 pretreatment [n  4] 29.5  5.9 A/cm2, P 
.05) and at 15 min after BIIE0246 addition to mouse
ucosa (controls [n  8] 8.7  2.3 A/cm2 versus pre-
reatment [n  8] 17.1  2.6 A/cm2, P  0.05).
To establish the relative contributions of endogenous
PY and PYY toward each Y-receptor–mediated tone, we
onitored the effects of Y1 or Y2 antagonists in colon
ucosa from single knockout mice (NPY/ or PYY/)
ig. 1. Y1 (3304) and Y2 (0246) antagonists reveal absorptive tone but 34
uman (A, B) and wild-type (C, D) mouse colon mucosa, respectively. Y
2 tone was significantly reduced by TTX pretreatment of both mucosae (B
ata groups (*P  0.05, **P  0.01, ***P  0.001) and bars represent me
etrodotoxin; 0246, BIIE0246; 3304, BIBO3304; 3435, BIBP3435.nd the double-null mice (NPYPYY/). Comparison of ohe maximal increases in Isc 15 min after antagonist addi-
ions in WT versus null mucosa showed that NPY/ colon
xhibited normal Y1 tone (that was not TTX sensitive; Fig.
A), whereas Y2 tone was partially (but not significantly)
educed by NPY ablation (Fig. 2B). TTX pretreatment of
PY/ tissue did not further inhibit Y1 or Y2 residual tone
Fig. 2A,B). In marked contrast, PYY/ mucosa was
arkedly less sensitive than WT colon to Y1 (Fig. 2C)
nd Y2 (Fig. 2D) antagonism and blocking neuronal ac-
ivity in this tissue abolished these residual increases in
sc. NPYPYY/ tissues were insensitive to both Y an-
agonists (Fig. 2A,B).
The NPYPYY/ colon lacked PYY endocrine cells and
PY-containing neurons in both intramural plexi, although
hromogranin A–stained endocrine cells and PGP9.5-
ositive neurons were present (data not shown). The
YY/ colon exhibited no obvious alteration in the pattern
inactive Y1 isomer) was ineffective. Y1 and Y2 antagonism raised Isc in
in both tissues was insensitive to TTX (TTX, 100 nM; A, C), whereas
Asterisks indicate statistical differences between control and experimental
SEM from 3–10 observations. Isc, change in short-circuit current; TTX,35 (an
1 tone
, D).
an f intramural NPY innervation, but PYY-positive cells were
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904 H. M. Cox / Nutrition 24 (2008) 900–906bsent. The NPY/ colon exhibited similar numbers of
YY-labeled endocrine cells (56.7  6.8 cells/section)
ompared with WT mucosa (55.0  4.6 cells/section) and
he morphology of WT and null tissues was similar.
iscussion
Y1 tone is clearly stereospecific and not mediated by
TX-sensitive enteric neurons in human and mouse colon
Fig. 1A,C). In contrast, Y2 tone is predominantly neuro-
enic (Fig. 1B,D), as described previously in normal human
olon and WT mouse mucosa [4,5]. The link between NPY
nd Y2 tone was initially revealed in ex vivo studies show-
ng that NPY/ and Y2/ tissues lost Y2 tone and were
ndistinguishable in this regard [7]. The present study in-
luded NPY/ mice from a source different from that used
reviously [7] but with a similar mixed genetic background
ig. 2. Effects of individual NPY or PYY ablation (NPY/, PYY/) an
A) WT Y1 tone was similar to that of NPY/ with or without TTX but
educed in NPY/ tissue with or without TTX (not significantly) and ab
YY/ colon (***P  0.001) and residual Y1 tone was abolished by neuro
*P  0.05) and abolished by TTX. Bars represent mean  SEM from 3
ingle knockout; NPYPYY/, peptide YY/neuropeptide Y double knockC57BL/6–129/SvJ). Apart from an elevation in basal Isc cnd TTX sensitivity in NPY/ compared with WT values
Table 1), there were no differences in electrophysiological
arameters between genotypes. Loss of inhibitory NPY
ould be partly responsible for the increase in basal Isc
evels if tonic activation of intrinsic submucous nerves is
ontributing to basal Isc. The increased effect of TTX on
asal Isc in NPY/ compared with WT values would also
onfirm this is the case.
The selective amplification of Y2 tone by DPP4 inhibi-
ion also indicates a significant tonic inhibition for endog-
nous NPY in human and mouse colon. Prolonging NPY’s
alf-life would result in potentiation of neurogenic re-
ponses and, because Y2 effects are primarily neuronal, they
ere increased, whereas the antisecretory actions of PYY at
pithelial Y1 receptors were not significantly altered. Pep-
ide levels before and after DPP4 inhibition will be mea-
ured to confirm the relative stability of NPY over PYY,
articularly at times when Y2 (but not Y1) tone is signifi-
ble knockout (NPYPYY/) on Y1 and Y2 tone in mouse colon mucosa.
bsent from NPYPYY/ tissues (**P  0.01). (B) Y2 tone was partially
d in NPYPYY/ preparations (*P  0.05). (C) Y1 tone was reduced in
ckade with TTX. (D) Y2 tone was partially inhibited in PYY/ mucosae
ervations. Isc, change in short-circuit current; NPY/, neuropeptide Y
YY/, peptide YY single knockout; TTX, tetrodotoxin; WT, wild-type.d dou
was a
olishe
nal blo
–7 obsantly amplified.
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905H. M. Cox / Nutrition 24 (2008) 900–906Knockout of individual peptides revealed clear differ-
nces in functional losses in the absence of any changes in
eptide distribution. The NPY/ colon exhibited normal
evels of Y1 tone that were not significantly altered by
euronal blockade, indicating a direct epithelial mechanism
f PYY action (Fig. 2A,B). This agrees with previous stud-
es of antisecretory responses activated by exogenous ana-
ogs [5,6] (Cox et al., unpublished observations). PYY ab-
ation conversely reduced Y1 tone by 90% (Fig. 2C),
hereas Y2 tone was partially inhibited (Fig. 2D) and the
emaining residual responses were abolished by TTX and
y inference must be NPY mediated. As predicted, double
nockouts lacked Y1 and Y2 tonic absorption (Fig. 2A,B).
e conclude that a combination of the two peptides are
esponsible for Y2 tonic absorption and that neuronal and
pithelial mechanisms underpin this tonic effect, as indi-
ated by the neurotoxin TTX’s ability to partially inhibit
ntagonist responses in NPY/ (Fig. 2B) and abolish re-
aining Y2 tone in the PYY/ colon (Fig. 2D). In contrast,
PY has a minor role as a mediator of Y1 tone (Fig. 2C).
he location of Y1 receptors in basolateral poles of epithelia
urrounding PYY-positive endocrine cells in human colon
26] fits well with the functional PYY–Y1 interactions ob-
ig. 3. Schematic diagram showing the intramural sites of action of en-
ogenous PYY and NPY in normal mouse and human colon mucosa.
irect activation of epithelial Y1 receptors by PYY (and NPY) will inhibit
pithelial anion (Cl) secretion. NPY released from submucosal secreto-
otor neurons can auto-inhibit its release (lefthand side, a Y2-mediated
ffect) and also, when released from interneurons, can inhibit (again via Y2
eceptors) secretomotor (e.g., VIP-ergic) neurons. Endocrine PYY can
o-activate neuronal Y2 receptors and predominant epithelial Y1 receptors,
nd both mechanisms result in sustained inhibition of epithelial Cl se-
retion. The NANC neurotransmitter in the final secretomotor neuron
righthand side) has yet to be positively identified but is likely to be VIP,
hich in turn stimulates prolonged epithelial cyclic adenosine mono-
hosphate–
ependent Cl secretion that can be inhibited by Y1 (or Y4) receptor
ctivation. NPY, neuropeptide Y; PYY, peptide YY; VIP, vasoactive
ntestinal polypeptide.erved in this tissue and in mouse colon (as shown in Fig. m). In these tissues we have no evidence for submucous
lexus or mucosal neuron Y1 expression and this agrees
ith the more limited distribution of Y1-receptor immuno-
eactivity noted by Matsuda et al. [27]. They observed only
1 labeling of myenteric nerves (removed with smooth
uscle from our preparations), a few endocrine-like cells,
nd specific larger blood vessels.
The selective inhibition of Y2 responses by TTX indicate
he absence of Y2 receptors in human and mouse colonic
pithelia, in contrast to previous studies of rat jejunum, where
unctional studies [29] and polymerase chain reaction–
ased detection of Y2 mRNA [28] showed epithelial Y2
xpression. We propose that activation of presynaptic Y2
eceptors by NPY and PYY inhibits secretomotor nerves
most probably vasoactive intestinal polypeptide–ergic) and
rovides a mechanism by which Y2 antagonism elevates
asal Isc and causes hypersecretion (Fig. 3) in human and
ouse colon. NPY released from other non-adrenergic,
on-cholinergic secretomotor nerves could auto-inhibit
PY release by Y2 receptor activation and local NPY,
PY(3–36), PYY, or PYY(3–36) could act on these neuro-
al Y2 receptors to modulate ongoing mucosal electrolyte
ecretion.
Ultimately, whatever the luminal or neural (vagal) stim-
lus, released PYY will rapidly activate several local (para-
rine) targets, primary among them, the epithelium. In ad-
ition to its hormonal effects that occur within minutes to
ours, PYY can also exert longer-term responses to alter
pithelial adhesion, differentiation, and increasing cell mi-
ration [31], potentially protecting against stimuli that cause
ucosal erosion. The same PYY/ mice that we have used
ave been shown to exhibit a more prominent female de-
elopment of mild late-onset obesity with a high-fat diet
30] and this outcome was not dissimilar to the age-related
eight gained by both genders of another PYY/ recently
escribed [32]. Whether hyperinsulinemia contributes to
his phenotype is not agreed but tonic inhibition afforded by
YY acting on Y1 receptors in pancreatic islets combined
ith Y2 inhibition of vagal output have been proposed [30]
s coincident contributing factors. It is interesting to note
hat PYY and NPY are responsible for Y1- and Y2-mediated
onic inhibition in central and peripheral targets including
he intestinal tract, where I have uncovered significant tonic
ctivity using selective Y1 and Y2 antagonists.
In conclusion, PYY and NPY exert common final anti-
ecretory actions but mediated by different pathways in-
olving two Y receptors (Y1 and Y2) with distinct distribu-
ions. The PYY-synthesizing L-cells of the large bowel play
pivotal role, not only in the regulation of satiety and ileal
rake but also in response to different luminal cues, e.g.,
atty acid chain length [33], resulting in predominant Y1
bsorptive responses. NPY exerts its inhibitory effects pre-
ominantly through submucous neuronal innervation of the
ucosa to bring about indirect Y2-mediated absorption and
oth tonically active mechanisms are present in human and
ouse colon mucosa.
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